MEDIVIR AB – INTERIM REPORT JANUARY – SEPTEMBER 2021

Positive MIV-818 data presented at ESMO. New positive data and renegotiated agreement for remetinostatJuly – SeptemberFinancial summary for the quarter · Net turnover amounted to SEK 0.8 (1.1) million. · The loss before interest, tax, depreciation and amortization (EBITDA) amounted to SEK -11.7 (5.2) million. Basic and diluted earnings per share amounted to SEK -0.26 (0.19) and SEK -0.26 (0.19) respectively. · Cash flow from operating activities amounted to SEK -20.0 (-17.1) million. · Liquid assets and short-term investments at the end of the period amounted to SEK 225.9 (